
1. j trop med hyg. 2017 aug;97(2):526-532. doi: 10.4269/ajtmh.16-0780.

sustained high cure rate artemether-lumefantrine uncomplicated
plasmodium falciparum malaria 8 years wide-scale use bagamoyo
district, tanzania.

mwaiswelo r(1), ngasala b(1), gil jp(2), malmberg m(3), jovel i(4), xu w(4),
premji z(1), mmbando bp(5), björkman a(4), mårtensson a(6).

author information: 
(1)department parasitology medical entomology, muhimbili university of
health allied sciences, dar es salaam, tanzania.
(2)drug resistance unit, division pharmacogenetics, department physiology
and pharmacology, karolinska institutet, stockholm, sweden.
(3)section virology, department biomedical sciences veterinary public
health, swedish university agricultural sciences, uppsala, sweden.
(4)department microbiology, tumor cell biology, karolinska institutet,
stockholm, sweden.
(5)national institute medical research, tanga centre, tanga, tanzania.
(6)department women's children's health, international maternal child 
health (imch), uppsala university, uppsala, sweden.

we assessed temporal trend artemether-lumefantrine (al) cure rate 8 
years wide-scale use treatment uncomplicated plasmodium falciparum 
malaria 2006 2014 bagamoyo district, tanzania. trend analysis was
performed four studies conducted 2006, 2007-2008, 2012-2013, 2014.
patients acute uncomplicated p. falciparum malaria enrolled, treated
with standard al regimen followed-up 3 (2006), 28 (2014), 42 (2012-2013),
or 56 (2007-2008) days clinical laboratory evaluation. primary outcome
was day 28 polymerase chain reaction (pcr)-adjusted cure rate across years from
2007 2014. parasite clearance slower 2006 2007-2008 cohorts
with less 50% patients cleared parasitemia day 1, rapid for
the 2012-2013 2014 cohorts. day 28 pcr-adjusted cure rate 168/170 (98.8%)
(95% confidence interval [ci], 97.2-100), 122/127 (96.1%) (95% ci, 92.6-99.5),
and 206/207 (99.5%) (95% ci, 98.6-100) 2007-2008, 2012-2013, 2014,
respectively. significant change trend cure rate between
2007 2014 (χ2trend test = 0.06, p = 0.90). pretreatment p. falciparum
multidrug-resistant gene 1 (pfmdr1) n86 prevalence increased significantly across
years 13/48 (27.1%) 2006 183/213 (85.9%) 2014 (p < 0.001), p.
falciparum chloroquine resistance transporter gene (pfcrt) k76 prevalence
increased significantly 24/47 (51.1%) 2006 198/205 (96.6%) 2014 (p 
< 0.001). al cure rate remained high 8 years wide-scale use in
bagamoyo district treatment uncomplicated p. falciparum malaria
despite increase prevalence pretreatment pfmdr1 n86 pfcrt k76
between 2006 2014.

doi: 10.4269/ajtmh.16-0780 
pmcid: pmc5544080
pmid: 28829723  [indexed medline]

